Preeminent Ophthalmologist, L. Jay Katz Joins Glaukos Corporation as Chief Medical Officer
February 22 2017 - 7:00AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology company focused on the development and commercialization
of breakthrough products and procedures designed to transform the
treatment of glaucoma, today announced that L. Jay Katz, MD, FACS,
has joined the company as Chief Medical Officer.
Dr. Katz is currently a practicing ophthalmologist, the Director
of Glaucoma Service at Wills Eye Hospital in Philadelphia and a
Professor of Ophthalmology at Jefferson Medical College at Thomas
Jefferson University. In addition, he has authored numerous books
on ophthalmology, published more than 200 articles in ophthalmic
journals and is on the editorial board for Journal of Glaucoma,
Survey of Ophthalmology, Graefe’s Archives of Clinical and
Experimental Ophthalmology and The Open Ophthalmology Journal.
After receiving his MD degree from Yale University Medical School
in 1979, Dr. Katz completed an internship in internal medicine at
the University of Virginia, a residency in ophthalmology at Yale
and a fellowship in glaucoma at Wills Eye Hospital.
Dr. Katz is actively involved in numerous ophthalmic
professional organizations and glaucoma foundations. He is a former
member of the board and past treasurer of the American Glaucoma
Society, a diplomate and associate examiner for the American Board
of Ophthalmology and a fellow, member-at-large and past president
of the Philadelphia Metro chapter of the American College of
Surgeons.
“We are delighted and honored to welcome Dr. Katz to our senior
leadership team,” said Thomas Burns, Glaukos President and Chief
Executive Officer. “As evidenced by his many professional
accomplishments and contributions to the practice of medicine, Dr.
Katz is among the world’s foremost experts on glaucoma. We are
confident that he will play an integral role in helping Glaukos
continue to pioneer the worldwide development and expansion of
Micro-Invasive Glaucoma Surgery, or MIGS.”
A former medical monitor for various Glaukos clinical trials,
Dr. Katz has also been an investigator in landmark glaucoma trials,
including the Advanced Glaucoma Intervention Study (AGIS) and
Collaborative Initial Glaucoma Treatment Study (CIGTS). In his role
as Glaukos Chief Medical Officer, Dr. Katz’s responsibilities will
include providing input and counsel on product development,
clinical trial designs and surgeon training; overseeing global
post-market medical safety programs; and collaborating with
academic institutions, professional societies, cooperative groups
and other strategic and scientific entities focused on the
understanding and advancement of glaucoma patient care.
“Glaucoma is an insidious, asymptomatic disease that causes
vision loss in millions of people worldwide,” said Dr. Katz. “I
have long admired and appreciated the innovative work Glaukos is
undertaking to provide new, viable treatment options for glaucoma
patients and the surgeons who care for them. I look forward to
beginning the next phase of my career as part of the Glaukos
organization as it continues to build MIGS awareness and adoption
across the clinical community while also pursuing a range of
promising next-generation therapies.“
In this new role, Dr. Katz will initially be employed by Glaukos
on a part-time basis, while maintaining his ophthalmology practice
in Philadelphia and involvement with clinical research and medical
education.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
company focused on the development and commercialization of
breakthrough products and procedures designed to transform the
treatment of glaucoma, one of the world’s leading causes of
blindness. The company pioneered Micro-Invasive Glaucoma Surgery,
or MIGS, to revolutionize the traditional glaucoma treatment and
management paradigm. Glaukos launched the iStent®, its first MIGS
device, in the United States in July 2012 and is leveraging its
platform technology to build a comprehensive and proprietary
portfolio of micro-scale injectable therapies designed to address
the complete range of glaucoma disease states and progression. The
company believes the iStent, measuring 1.0 mm long and 0.33 mm
wide, is the smallest medical device ever approved by the FDA.
Forward-Looking Statements
All statements other than statements of historical facts
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements. Although we
believe that we have a reasonable basis for forward-looking
statements contained herein, we caution you that they are based on
current expectations about future events affecting us and are
subject to risks, uncertainties and factors relating to our
operations and business environment, all of which are difficult to
predict and many of which are beyond our control, that may cause
our actual results to differ materially from those expressed or
implied by forward-looking statements in this press release. These
potential risks and uncertainties include, without limitations, our
ability to continue to pioneer the worldwide development and
expansion of MIGs and products for the treatment of glaucoma. These
risks, uncertainties and factors are described in detail under the
caption “Risk Factors” and elsewhere in our filings with the
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2016 filed with
the Securities and Exchange Commission. Our filings with the
Securities and Exchange Commission are available in the Investor
Section of our website at www.glaukos.com or at www.sec.gov. In
addition, information about the risks and benefits of our products
is available on our website at www.glaukos.com. All forward-looking
statements included in this press release are expressly qualified
in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on the forward-looking
statements in this press release, which speak only as of the date
hereof. We do not undertake any obligation to update, amend or
clarify these forward-looking statements whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170222005357/en/
for Glaukos CorporationMedia Contact:Cassandra Dump(619)
971-1887cassy@pascalecommunications.comorInvestor
Contact:Sheree AronsonVP, Investor Relations(949) 367-9600 ext
371saronson@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Apr 2023 to Apr 2024